In breast and stomach cancer, it serves as a prognostic and predictive biomarker [11,12], and, therefore, HER2-targeted therapy has been adopted as a major part of the current standard regimen in HER2 overexpressed or amplified breast and stomach cancer [13,14,15]. This evidence concerns the gene ERBB2 and gastric neoplasm.